Recent advances in the neurobiology of FXS have suggested that many of the phenotypic features of the disorder arise from enhanced activity of translational activation pathways regulated by metabotropic glutamate receptors 1 and 5 (mGluR1, mGluR5), as a result of absence of FMRP [7]. This evidence concerns the gene FMR1 and fragile X syndrome.